HARP News and Press, Harpoon Therapeutics Inc. From 11/15/22

Harpoon Therapeutics press release ( NASDAQ: HARP ): Q3 GAAP EPS of -$0.35 beats by $0.20 . Revenue of $13.6M (+203.6% Y/Y) beats by $7.25M . Harpoon ended the third quarter of 2022 with $66.1M in cash, cash equivalents and marketable securities, compared to $1...

HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing clinical programs; restructuring workforce to support prioritized clinical dev...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present updated interim data from its Phase 1 clinical trial evaluating single...

After AstraZeneca ( AZN ) unit Alexion ( AZN ) agreed to acquire nano-cap LogicBio ( LOGC ), paying over 660% premium on Monday, Cantor sees further acquisitions for smaller cap firms where valuations have come under pressure despite their attractive assets/ platforms. ...

Harpoon Therapeutics ( NASDAQ: HARP ) has announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead the clinical development strategy and its execution for Harpoon Therapeutics and the product candidates derived from the company&#x...

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead t...

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Lauren Silvernail to its Board of Directors and as the Chairperson...

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in three upcoming investor conferences: Conduct one-on...

Summary Harpoon Therapeutics is an oncology platform play developing tri-specific drug candidates. The company’s lead candidates HPN217 and HPN328 are in Phase 1/2 trials and have so far shown efficacy without compromising safety. HPN217’s main takeaway is its Ab...

Harpoon Therapeutics press release ( NASDAQ: HARP ): Q2 GAAP EPS of -$0.53 beats by $0.03 . Revenue of $8.3M (+43.1% Y/Y) beats by $1.34M . For further details see: Harpoon Therapeutics GAAP EPS of -$0.53 beats by $0.03, revenue of $8.3M beats by $1.34M ...